Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. (Q43470326)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Hirotaka Watada

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Maximilian von Eynatten

9

object named as

M von Eynatten

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

E Araki

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

R Kawamori

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

N Hayashi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Y Horie

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

A Sarashina

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

S Thiemann

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

K Dugi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

H-J Woerle

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

7 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

364-371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus

18 February 2020

cites work

1 reference

Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15).

21 January 2018

1 reference

Incretin-based therapies: viewpoints on the way to consensus

21 January 2018

1 reference

Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice

21 January 2018

1 reference

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

21 January 2018

1 reference

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjec

21 January 2018

1 reference

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

21 January 2018

1 reference

Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo

21 January 2018

1 reference

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase

21 January 2018

1 reference

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

21 January 2018

1 reference

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes

21 January 2018

1 reference

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12039

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163910%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference